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S
ince the sentinel discovery of the first heritable monogenic cardiovascular disease (CVD) genes in the early to mid 1990s, genetic testing for familial aortopathies, 1,2 cardiomyopathies, 3, 4 cardiac channelopathies, 5, 6 and hypercholesterolemia 7, 8 has transitioned rapidly from early research-based endeavors to a full complement of reimbursable commercially available genetic tests. Furthermore, following the release of the first complete human genome sequences in 2001, 9 ,10 ensuing genome-wide association studies (GWASs) have identified a plethora of common genetic variants that underlie risk for development of common CVDs such as coronary heart disease (CHD) 11 and atrial fibrillation (AF) 12 as well as interindividual variability in cardiovascular drug response. Collectively, genetic testing for rare monogenic CVDs, ongoing development of genetic risk scores (GRSs) for common polygenic CVDs, and the implementation of pharmacogenomic testing to predict response to cardiovascular drugs represent the spectrum of genetic tests that currently impact the diagnosis, risk stratification, and clinical management of patients with rare and common CVDs.
With the announcement of the Precision Medicine Initiative in early 2015, interest in precision genomic medicine has intensified, and the stage has been set for an unprecedented proliferation of genetics-and genomics-guided approaches. Although cardiovascular health care professionals stand to benefit from these advances, the rapid pace of genomic discoveries, gaps in genomics education/literacy, and the paucity of data from randomized controlled trials (RCTs) designed to determine the clinical utility of genomics-aided approaches have left many overwhelmed and thereby ill-prepared to deliver high-quality, genomics/geneticseguided care. As such, this review aims to summarize the current clinical utility, commonly encountered pitfalls, and areas of emerging interest pertaining to the use of genetic and pharmacogenomic testing to individualize the clinical management of an array of CVDs.
BASIC PRINCIPLES GOVERNING THE INITIATION AND INTERPRETATION OF CARDIOVASCULAR GENETIC TESTS
With each passing year, cost-lowering technological advances, improved payer reimbursement, and legislation aimed at eliminating genetic discrimination make genetic testing increasingly accessible and appealing. However, as the pendulum has swung from inaccessible to more readily available, the increased, and at times inappropriate, utilization of genetic testing has brought a new set of obstacles. 13 As such, the ensuing paragraphs aim to help physicians avoid common pitfalls associated with the inappropriate use of genetic testing, namely, poor phenotyping, inappropriate genetic test selection, and misinterpretation of results, by outlining common indications, expected results, and basic interpretive strategies when considering CVD genetic testing.
At present, CVD genetic testing is reserved typically for 1 of 3 clinical indications:
(1) comprehensive genetic testing to aid or confirm the diagnosis of a heritable CVD for which there is a strong index of clinical suspicion (class I recommendation for many, but not all, monogenic CVDs), 6 (2) mutationspecific cascade screening of appropriate relatives (class I recommendation for all monogenic CVDs), 6 and (3) the selected use of pharmacogenomic testing to aid in the selection and/or dosing of certain cardiovascular medications (variable society and regulatory agency recommendations). It is important to note that due to variable expressivity and incomplete penetrance of monogenic CVDs coupled with substantial background genetic variation in many monogenic CVD-causative genes, diagnostic genetic testing should be viewed as probabilistic rather than binary/ deterministic. 5, 14, 15 As such, the clinical utility of a given genetic test is highly dependent on the pretest probability of disease (ie, strength of clinical phenotype/diagnosis) and disease-specific genetic test performance metrics (eg, diagnostic yield, signal to noise ratio). In other words, in patients with weak/nonequivocal clinical phenotypes, the diagnostic yield of genetic testing declines, the signal to noise ratio rises, and the risk of encountering falsepositive results increases exponentially. Therefore, a "one size fits all" mentality to genetic testing is ill-advised, and genetic testing should be undertaken only if considerable suspicion for an underlying genetic CVD remains after a thorough clinical evaluation, including, but not limited to, a detailed family history, comprehensive cardiovascular work-up, and assessment for multisystem syndromes. Given these nuances, the initiation and interpretation of cardiovascular genetic tests requires a multidisciplinary approach involving the coordinated efforts of general practitioners/general cardiologists, genetic counselors, medical geneticists, and cardiovascular subspecialists (4) assuring that psychosocial ramifications of genetic testing are adequately addressed, genetic counseling provides additional assurance that genetic testing will be utilized appropriately and that high-quality, costeffective care is delivered. 16 Once a decision is made to pursue genetic testing and the patient is apprised of the potential risks, benefits, and limitations of genetic testing (ideally by a genetic counselor), including the fact that a negative test result cannot definitively rule out disease (except for the case of mutation-specific cascade screening) and variants of unknown/uncertain significance (VUSs) without sufficient supporting evidence to be deemed pathogenic may be encountered, the work is far from over. First, the genetic test results should be interpreted in light of established criteria set forth by the American College of Medical Genetics and Genomics (ACMG) 17 and other organizations as summarized in Figure 1 . In some instances, a bona fide pathogenic mutation meeting the ACMG's standards for very strong/strong evidence of pathogenicity (ie, null, established, and de novo variants as outlined in Figure 1 ) 17 is unearthed, making interpretation straightforward.
However, in many cases, the commercial genetic test reports will return "positive" results with cryptic language such as "possible deleterious mutation" or "VUS" next to the identified variant(s). In this scenario, it is important to realize that "positive" is not synonymous with "disease-causative" because in many circumstances, the identified VUS has a nearly equal chance of being either a pathogenic mutation or a rare innocuous variant. When there is insufficient evidence to tip the scale in either direction, an agonizing situation for patients and physicians develops, recently referred to as "genetic purgatory." 13, 18 Although genetic purgatory is a situation all health care professionals hope to avoid, once there it is imperative to resist the temptation to act on a VUS by (1) escalating clinical management of the index case and/or (2) initiating mutation/ variantespecific cascade screening because they can lead to potentially harmful diagnostic miscues. Rather, physicians need to closely scrutinize available data and intermittently reassess the potential pathogenicity of the VUS in light of any new clinical, molecular, or computational data that may elevate or downgrade its status based on the ACMG's pathogenicity framework (Figure 1 ). 17 
GENETIC TESTING FOR COMMONLY ENCOUNTERED MONOGENIC (MENDELIAN) CVDS
Classically, monogenic or Mendelian disorders arise from a rare mutation(s), passed from generation to generation in defined inheritance patterns (eg, autosomal dominant, autosomal recessive, X-linked) that perturb the intended biological function of a single diseasecausative, gene-encoded protein ( Figure 2 ). 19 FIGURE 1. A rational approach to cardiovascular genetic testing, rare variant interpretation, and the reassessment of variants of unknown/uncertain significance. Light orange boxes denote basic considerations pertaining to the initiation of genetic testing. Yellow boxes denote key steps in the classification of rare genetic variation based on American College of Medical Genetics and Genomics (ACMG) criteria. Blue boxes denote basic considerations pertaining to the identification of a rare variant of unknown/uncertain significance that currently lacks sufficient evidence to either upgrade or downgrade its probability of pathogenicity. Allele frequency of more than 5% or greater than widely accepted estimates of disease prevalence in the Exome Aggregation Consortium (ExAC), Exome Sequencing Project (ESP), or 1000 Genomes Project serve as standalone or strong evidence that a variant is likely benign, respectively. GOF ¼ gain of function; LOF ¼ loss of function; WT ¼ wild-type.
In the subsequent sections, we summarize the current state of diagnostic clinical genetic testing for 4 commonly encountered classes of monogenic CVDs (aortopathies, cardiomyopathies, cardiac channelopathies, and familial hypercholesteremia) and how the judicious utilization of genetic testing can enhance and in some cases individualize the diagnosis, risk stratification, and/or clinical management of patients with these potentially life-threatening disorders.
Aortopathies
The thoracic aortopathies include a spectrum of heritable connective tissue disorders such as Marfan syndrome (MFS), Loeys-Dietz syndrome, and vascular Ehlers-Danlos syndrome, that largely arise secondary to dysregulated transforming growth factor b signaling and predispose affected individuals to aortic dilatation/aneurysm, premature death secondary to aortic dissection/rupture, and a host of variable overlapping cardiac (eg, arrhythmia, valvular dysfunction) and extracardiac (eg, ophthalmologic, orthopedic) manifestations.
1,2 In addition, thoracic aortic aneurysm and dissection without evident systemic connective tissue abnormalities can occur in families, often in an autosomal dominant fashion. Mutations in several genes have been implicated in such syndromes of familial thoracic aortic aneurysm and dissection. Current commercially available genetic testing panels cover approximately 16 aortopathy-susceptibility genes responsible for at least 6 distinct clinical entities as detailed in Table 1 .
Although a relative paucity of clinically relevant genotype-phenotype correlations exist for the aortopathies, mutations within exons 24 through 32 of the MFS-causative FBN1 gene (for expansion of gene symbols, see www.genenames.org) that encodes fibrillin 1 are associated with a form of atypically severe, early-onset MFS classically referred to as neonatal MFS. 25 Emerging evidence also suggests that patients with MFS who have haploinsufficient FBN1 mutations (truncating/frameshift mutations that fail to produce a protein product) are at greater risk for premature aortic events/cardiovascular death 26, 27 and may be more responsive to angiotensin-receptor blockers 28 than counterparts with dominant-negative FBN1 mutations (missense/exoneskipping mutations that yield an aberrantly functioning protein). As such, the clinical utility of genetic testing for these disorders is confined to (1) diagnostic confirmation in patients with a high pretest probability of disease (eg, FBN1 testing in patients with MFS who meet revised Ghent criteria), (2) cascade genetic screening starting with first-degree relatives to identify those who would benefit from imaging surveillance and those who potentially can be dismissed, and (3) allowing for differentiation between clinical entities given the degree of phenotypic overlap, particularly since the current American College of Cardiology/American Heart Association thoracic aortic disease recommendations regarding surveillance imaging and timing of surgical intervention differ between MFS, Loeys-Dietz syndrome, and vascular Ehlers-Danlos syndrome. 20 An overview of available society recommendations and the clinical utility of genetic testing for the heritable thoracic aortopathies is presented in Table 1 .
Cardiomyopathies
The inherited cardiomyopathies are a group of phenotypically and genetically heterogeneous heart failuree and sudden cardiac death (SCD)epredisposing CVDs that arise secondary to mutations in genes that encode key cardiomyocyte structural components (eg, myofilaments, Z disk, desmosome) and are classified by functional and morphological features as arrhythmogenic cardiomyopathy (ACM) (previously referred to as arrhythmogenic right ventricular cardiomyopathy/ dysplasia), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), left ventricular noncompaction (LVNC), or restrictive cardiomyopathy (RCM). 3 Given the considerable phenotypic and genetic overlap among these cardiomyopathies, the use of commercial pancardiomyopathy gene panels has gained favor, particularly in cases in which the addition of molecular insights affords an opportunity to further refine the clinical diagnosis. However, the use of large gene panels is likely best reserved for individuals who have undergone all conventional cardiomyopathyspecific genetic testing because (1) nearly half of the more than 60 cardiomyopathy-susceptibility genes identified to date lack sufficient evidence to be considered as bona fide disease-susceptibility genes and are considered "limited evidence genes," 29, 30 (2) next-generation sequencingebased panels further complicate the already difficult task of differentiating rare benign genetic variation from disease-causative mutations by enhancing the detection of low-frequency benign variants, and (3) current society guidelines recommend comprehensive/targeted diagnostic screening of only those genes commonly and/or very strongly associated with the clinically suspected cardiomyopathy (eg, myofilament only for HCM, desmosome only for ACM) (Table 1) . 6, 23, 31 In general, the lack of disease-modifying therapies limits the clinical utility of cardiomyopathy genetic testing to diagnosis and prognostication/risk stratification. Multiple common variants (>5%) with weak effects incapable of producing disease in isolation FIGURE 2. The spectrum of genetic variation underlying the heritable component of commonly encountered cardiovascular disorders (CVDs). At the severe (orange) end of the spectrum are extremely rare disease-causative mutations with strong effects on gene function that typically result in monogenic disorders such as long QT syndrome, hypertrophic cardiomyopathy, and familial hypercholesterolemia.
(FH). In the middle of the spectrum (blue) are rare variants with moderate effects on gene function that rarely produce disease in isolation but in the presence of one or more second hits result in disease as seen in some instances of arrhythmogenic cardiomyopathy. Lastly, at the benign (brown) end of the spectrum are common variants with weak effects on gene function that may confer disease risk when multiple riskassociated common variants are present together with environmental risk factors for disorders such as coronary heart disease (CHD) and atrial fibrillation (AF). In recognition that the genetic basis of most heritable CVDs is variable, yellow triangles denote the spectrum of genetic variation underlying each CVD or class of CVDs. Adapted from Transl Res, 19 with permission from Elsevier. Continued on next page 
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treatment with enzyme replacement therapy. In addition, patients with DCM secondary to mutations in either LMNA-encoded lamin A and C or DES-encoded desmin are at much higher risk for conduction disease and/or malignant arrhythmias/SCD. [33] [34] [35] In such cases, genetic testing may guide the use of implantable cardioverter-defibrillators as primary prevention.
Due to a relative paucity of clinically relevant genotype-phenotype correlations, genetic testing for ACM, DCM, LVNC, and RCM is currently recommended for diagnostic confirmation in the proband and cascade testing of at-risk relatives (Table 1 ). Although few clinically relevant gene-or mutation-specific genotype-phenotype correlations exist in HCM, multiple studies have found that individuals with genotype-positive HCM (ie, a positive genetic test result), particularly those with mutations in the cardiac myofilaments, have a more severe clinical phenotype (younger age at diagnosis, more hypertrophy, higher rate of progression to New York Heart Association class III/IV heart failure, and risk of cardiovascular death) compared with patients who have HCM but a negative genetic test result (ie, heretofore genotype-negative HCM). [36] [37] [38] [39] Furthermore, in comparison to individuals with thin-filament HCM (ACTC1, TNNI3, TNNT2, and TPM1), those with thick myofilament HCM (MYH7 and MYBPC3) have more severe hypertrophy as well as higher rates of left ventricular outflow tract obstruction and progression to New York Heart Association class III/IV heart failure but no difference in the risk of arrhythmia/SCD. 40 Lastly, approximately 5% to 10% of individuals with HCM and ACM harbor more than one diseasecausative mutation, resulting in so-called compound or digenic heterozygosity that is associated typically with a more severe clinical phenotype. [41] [42] [43] [44] These observations, coupled with the genotype-phenotype discordance related to inherited cardiomyopathies in recent largescale exome sequencing studies, 45 suggest that (1) many genetic variants in cardiomyopathy-susceptibility genes that were previously believed to be pathogenic may be merely disease modifiers or nonpathogenic altogether and/or (2) the classic monogenic/Mendelian autosomal-dominant mode of inheritance may be an oversimplification, particularly for ACM in which a substantial number of patients harbor more than one putative ACM-causative mutation 41, 42 Collectively, this suggests that an oligogenic model whereby 2 or more hits in genes encoding the same functional unit (eg, desmosome, sarcomere) are required to produce overt disease may ultimately prove to be best fit for even these "monogenic" forms of genetic heart disease ( Figure 2) .
In summary, mutation-specific cascade testing of appropriate relatives remains a class I recommendation for all inherited cardiomyopathies once a disease-causative mutation is identified in an index case. In contrast, owing to the genetic complexity of these disorders, the challenges associated with evaluating the pathogenicity of rare variants, and the paucity of clinically useful genotype-phenotype correlations at present, diagnostic genetic testing of the index case is a class I recommendation only for patients with either HCM or those with DCM and severe cardiac conduction disease (Table 1) . 6 It is anticipated that ongoing and future longitudinal studies that couple next-generation sequencingeaided genotyping with in-depth clinical phenotyping may yield the additional insights necessary to further define the optimal role of genetic testing for patients with suspected ACM, DCM, LVNC, and RCM. Until then, recommendations for genetic testing for patients with these cardiomyopathies are designated as class IIa/IIb (Table 1) . 6 
Cardiac Channelopathies
The term cardiac channelopathies is used colloquially to describe a set of clinically and genetically diverse heritable cardiac arrhythmia syndromes, including Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and long QT syndrome (LQTS). These channelopathies collectively arise from defects in either critical cardiac ion channel macromolecular complexes or proteins critical for intracellular calcium handling. Patients with a channelopathy typically have a structurally normal heart but are predisposed to arrhythmic syncope/seizures and SCD. 5, 46 More than 40 channelopathy-susceptibility genes have been described to date, and most commercially available genetic tests cover at least 20 of these genes through the use of disease-specific tests or comprehensive panchannelopathy gene panels as outlined in Table 2 .
Similar to the cardiomyopathies, the firstline use of commercial channelopathy panels should be approached with great caution because the inclusion of channelopathysusceptibility genes without definitive clinical association and the enhanced detection of low-frequency variants can confound the already difficult task of rare variant interpretation. Although the clinical utility of genetic testing in the diagnosis of cardiac channelopathies is well established and evidenced by recent Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA) recommendations, 6 LQTS, with its robust genotypephenotype correlations, represents one of the few monogenic CVDs in which genetic testing facilitates a genomic/geneticeguided approach to both risk stratification and treatment and is therefore the focus of the ensuing paragraphs.
Among clinically definitive LQTS cases (ie, heart rateecorrected QT interval 480 ms and Schwartz score 3.5), 49 approximately 75% have a mutation in 1 of the 3 canonical LQTS-susceptibility genes, the KCNQ1-encoded Kv7.1 potassium channel (LQT1, w35%), the KCNH2-encoded Kv11.1/hERG potassium channel (LQT2, w30%), or the SCN5A-encoded Nav1.5 sodium channel (LQT3, w10%), with an additional approximately 5% to 10% expected to harbor mutations in the remaining 14 "minor" LQTS-susceptibility genes. 50, 51 Even among the 3 major LQTS-susceptibility genes, there is a substantial rate of background genetic noise (w2.7% of more than 60,000 individuals in the Exome Aggregation Consortium cohort harbor rare amino acidealtering genetic variation in the major LQTS genes). 13, 14 This feature complicates LQTS genetic test interpretation to the extent that occasional calls for universal LQTS genetic testing must be deemed ill-informed. However, when viewed in the context of an individual's entire clinical picture (eg, nongenetic risk factors such as age, sex, and degree of QT prolongation) and the established genotype-phenotype correlations (eg, genotype-specific triggers and genotype-dependent responsiveness to primary therapy, ie, b-blockers), the identification of a putative mutation in one of the major LQTSsusceptibility genes enables genotype-specific approaches to risk stratification and clinical management. 49 Unfortunately, a seemingly positive genetic test result for a minor LQTS gene, with the notable exception of exceedingly rare multisystem forms of LQTS such as Timothy syndrome (CACNA1C), Andersen-Tawil syndrome (KCNJ2), the calmodulinopathies (CALM1, CALM2, CALM3), and triadin knockout syndrome (TRDN), 49, 52 does not carry the same weight as the major LQTS subtypes and thus contributes little to risk stratification and clinical management. 13 Current HRS/EHRA guidelines recommend (class I) LQTS genetic testing for any individual in whom LQTS is strongly suspected on the basis of clinical/family history and electrocardiographic phenotype and in asymptomatic individuals with unexplained serial QT prolongation (>480 ms before puberty and >500 ms after puberty). 6 Similarly, under current HRS/ EHRA guidelines, comprehensive or targeted genetic testing for individuals in whom there is strong clinical suspicion for CPVT is recommended, whereas targeted screening of the SCN5A-encoded Nav1.5 sodium channel can be useful in establishing a diagnosis of BrS in individuals in whom there is a strong clinical suspicion of disease based on clinical/family history and electrocardiographic phenotype. 6 Lastly, given that many patients with genotype-positive LQTS, BrS, and CPVT do not manifest clinical/electrocardiographic evidence of disease at baseline, mutation/variantespecific cascade screening of all at-risk relatives is recommended by the HRS/EHRA following the identification of a channelopathy-susceptibility mutation in an index case. 6 Familial Hypercholesterolemia Familial hypercholesterolemia (FH) is a relatively common 47, 48, 53, 54 predominantly autosomal dominant disorder of lipid/lipoprotein metabolism characterized clinically by elevated low-density lipoprotein cholesterol (LDL-C) levels, tendon (xanthoma) and corneal (corneal arcus) cholesterol deposition, and if untreated, a high risk for premature atherosclerotic CVD. 7 Because of the relatively high prevalence of FH across all racial/ethnic groups and the devastating complications of unrecognized/untreated disease, FH is the only monogenic CVD that currently meets World Health Organization criteria for universal population-based screening. 8, 55 Although current National Heart, Lung, and Blood Institute expert guidelines recommend universal lipid screening for children aged 9 to 11 years, 56 the rate of prepubertal lipid screening in the United States is low (w10%), 57 and the optimal approach to universal FH screening remains undefined (ie, lipid screening alone vs lipid screening followed by family-based cascade genetic screening). 8, 57 In recent years, the recognition of an overlap in LDL-C levels between mutation-positive and mutation-negative relatives 58 as well as between individuals with heterozygous FH (single mutation in a FH-susceptibility gene) 47, 53 and homozygous/compound heterozygous FH (>1 mutation in FH-susceptibility gene[s]) 59 has led to an increased reliance on genetic testing. Specifically, the World Health Organization 60 and the European Atherosclerosis Society 47 both recommend family-based genetic cascade screening once a mutation-positive index case is identified. The role of genetic testing in FH is further highlighted by the incorporation of genetic test results into the 2 most commonly employed sets of validated FH diagnostic clinical criteria, the Dutch Lipid Clinic Network 61 and Simon Broome Registry criteria. 58 Although 6 FH-susceptibility genes have been discovered to date (Table 2) , most commercially available panels and expert recommendations focus on initial sequencing and deletion/duplication analysis of 3 key genes (LDLR, APOB, and PCSK9) that account for more than 90% of mutation-positive, clinically definite FH cases. 47 Similar to other genetic disorders, the overall diagnostic yield of FH is dependent on the pretest probability of disease (eg, 63% for definite, 35% for probable, and 22% for possible FH based on Dutch Lipid Clinic Network criteria), 62 and the major FH-susceptibility genes are also subject to an inherent rate of background genetic variation. Thus, FH genetic test results should be interpreted in light of the aforementioned ACMG guidelines. 17 As such, the primary clinical utility of FH genetic testing is (1) to confirm diagnosis/identify FH-causative mutation in individuals with a definite/probable clinical diagnosis of FH (eg, adults with LDL-C levels >190 mg/dL [to convert to mmol/L, multiply by 0.0259] and children with LDL-C levels >160 mg/dL and personal/family history of premature atherosclerotic CVD or tendinous xanthomas) and (2) to facilitate cascade screening of first-, second-, and third-degree relatives of mutation-positive FH index cases.
Although several genetic variants that influence phenotypic severity 59, 63 and statin responsiveness have been identified, 64 risk stratification and clinical management decisions in FH are currently driven by LDL-C levels and therapeutic response. It is likely that as additional genetic variants with modest effects on LDL-C that modulate the phenotypic expression of primary FH-causative mutations are discovered, the role of genetics in tailoring individualized approaches to the risk stratification and management of patients with FH will continue to grow.
GENETIC TESTING FOR CARDIOVASCULAR DIAGNOSTIC ODYSSEYS
The term diagnostic odyssey refers to any patient or family with a suspected genetic disorder in which the precise underlying clinical entity remains undifferentiated following standard genetic testing. 65 With its ability to detect changes throughout the coding regions of the human genome and increasingly cost-effectiveness, whole-exome sequencing (WES) is proving to be a valuable diagnostic clinical tool for elucidating the genetic etiology of diagnostic odysseys. [66] [67] [68] In fact, WES has been successful in elucidating an underlying genetic basis for approximately 25% of diagnostic odysseys 65, [69] [70] [71] and in numerous cases has led to the identification of novel monogenic/Mendelian CVD-susceptibility genes/genetic loci in patients with seemingly genotype-negative disease. [66] [67] [68] In addition to the use of clinical WES to investigate cardiovascular diagnostic odysseys in living patients, several groups have explored the utility of WES-based molecular autopsies (WEMA) [72] [73] [74] [75] [76] [77] as a cost-effective means of screening cases of sudden unexplained death in the young (SUDY) for previously undiagnosed SCD-predisposing monogenic/Mendelian CVDs, such as the cardiac channelopathies and cardiomyopathies, that are often undetectable on autopsy and known to underlie approximately 25% to 35% of SUDY cases. 73, 76, 78 Although most of these studies, including a recent population-based prospective trial that utilized a 55ecardiac gene panel, 76 identified clinically actionable variants and increased the overall diagnostic yield in SUDY, [73] [74] [75] [76] the use of large cardiac gene panels to probe ambiguous phenotypes such as SUDY should be approached with caution. Not only do these gene panels contain a substantial number of polymorphic genes that collectively have the ability to produce an overwhelming amount of background genetic noise, but SUDY phenotypes also are often poorly defined, making it next to impossible to interpret suspected SUDY-causative variants in the context of the pretest probability of any single heritable CVD. As a result, the use of WEMAs is likely to unearth many ultrarare VUSs in potential SUDY-susceptibility genes, and the bulk of these variants will lack the supporting evidence needed to definitively assign pathogenicity. One can envision how the results of a 50-to 100-gene WEMA could be misinterpreted easily by well-intentioned clinicians, triggering the misguided cascade screening of at-risk relatives. As such, a tiered approach to WEMA starting with those genes most likely to harbor clinically actionable variants based on prior SUDY studies (eg, KCNQ1, KCNH2, SCN5A, RYR2, PKP2, CALM1, CALM2, CALM3) 74, 75 is advisable and consistent with current HRS/EHRA recommendations when performed in conjunction with a comprehensive postmortem examination and clinical/cardiologic evaluation of first-degree relatives. 6 
GRSS IN THE PREDICTION AND PREVENTION OF POLYGENIC (NON-MENDELIAN) CVDS
In contrast to monogenic/oligogenic CVDs that typically arise from a rare, single gene mutation(s), many common CVDs, including AF, CHD, and hypertension, have a clear heritable component attributable to the collective contribution of multiple independent or interacting variants that in isolation account for a small fraction of the complex trait or disease in question resulting in a so-called polygenic inheritance pattern (Figure 2) . 79, 80 Although currently no commercial genetic tests are available for so-called polygenic CVDs, the following paragraphs briefly examine ongoing efforts to translate CVD-associated singlenucleotide polymorphisms (SNPs)/genetic loci discovered through GWAS into a clinically useful aggregate GRS that, in conjunction with traditional clinical risk factors, can enhance risk stratification and prevention of polygenic CVDs.
Over the past decade, multicohort GWAS meta-analyses led by trans-Atlantic consortia such as the Atrial Fibrillation (AFGen), 12 Global Blood Pressure Genetics (BPgen), 81 and Coronary Artery Disease Genome-wide Replication and Meta-analysis (CARDIo-GRAM) 11 consortia have yielded a large number of CVD-associated SNPs/genetic loci that reach genome-wide significance. However, because of the small effect size of each individual SNP, the clinical utility of individual SNPs to predict disease likelihood is modest. 82 As a result, the concept of a GRS was conceived. 83 In this method, a panel of weighted or unweighted disease-susceptibility SNPs is used to generate a single aggregate score that undergoes subsequent predictive modeling (ie, the area under the receiver operating characteristic curve or net reclassification improvement index) to determine if the GRS improves predictive capacity and therefore may have clinical utility, incremental to traditional clinical risk factors. 83 To date, several GRS studies have found a relatively modest but statistically significant incremental predictive ability for incident AF 84, 85 and CHD risk/adverse events. [86] [87] [88] [89] [90] [91] , The Myocardial Infarction Genes (MI-GENES) clinical trial revealed that the incorporation of a CHD GRS into a conventional risk prediction algorithm and subsequent disclosure of genetic risk for CHD to study participants led to lower LDL-C levels than disclosure of clinical risk factors alone. 92 Furthermore, disclosure of CHD genetic risk did not induce anxiety. 92 As such, the knowledge of an underlying genetic predisposition to common polygenic CVDs may lower the overall burden of CVD by prompting physicians and patients to more aggressively address modifiable risk factors before disease onset (Figure 3) . However, because most of the CVD GWAS metaanalyses were conducted in cohorts of European ancestry, ongoing studies are needed to ascertain whether the current CVD GRSs can be generalized to other racial/ethnic groups.
Lastly, large prospective clinical trials are needed to determine if the use of a CVD GRS can improve clinical outcomes, decrease disease burden, and lower health care costs.
CARDIOVASCULAR PHARMACOGENOMICS
Drugs used in the prevention and treatment of CVD, including b-blockers, flecainide, clopidogrel, statins, and warfarin, account for many of the most widely prescribed pharmacological agents worldwide. Although these drugs are highly effective and safe at the population level, individual patients occasionally display variability in the degree of efficacy and/or rate of adverse drug reactions. This clinical conundrum birthed the field of pharmacogenomics, which aims to enhance the utility of available pharmacological agents by linking variation in genes that govern a drug's pharmacokinetic (effect of the body on drug concentration/tissue distribution) and pharmacodynamic (effect of the drug on body molecular/cellular/organ function) properties to interindividual variability in drug response. Furthermore, the concept of preemptive pharmacogenomics, wherein individuals are genotyped for relevant pharmacogenomic genes/variants and actionable results are then placed in the electronic health record with linkage to clinical decision support, is being pursued actively. 93 Due to a relative paucity of RCTs aimed at defining the clinical utility of pharmacogenomics testing and the availability of alternative agents with decreased or no known pharmacogenomic liability, current society and regulatory agency recommendations/ guidelines vary in regard to the use of pharmacogenomics testing in clinical practice (Table 3) . [94] [95] [96] [97] Although a thorough discussion of cardiovascular pharmacogenomics is outside the scope of this review, current professional society and regulatory agency recommendations/guidelines pertaining to the use of pharmacogenomics testing when prescribing b-blockers, clopidogrel, statins, and warfarin are outlined in Table 3 , and an expanded discussion of how pharmacogenomics data may be used to individualize cardiovascular drug and dosage selection is contained in the Supplemental Material (available online at http://www.mayoclinicproceedings.org). CONCLUSION Although this review details many examples of how genetic testing has already led or will one day lead to genotype-guided approaches to the diagnosis, risk stratification, and management of patients with an array of CVDs, the full promise of precision genomic medicine is far from being realized. As echoed throughout this review, a number of barriers currently limit and complicate the use of genetic testing in clinical practice. As such, it is imperative that innovative, welldesigned, and adequately powered studies are undertaken to (1) elucidate genotypephenotype correlations utilized in the development of individualized genotype-guided approaches to the risk stratification and management of monogenic CVDs, (2) enhance the ability to distinguish pathogenic mutations from rare, benign, background genetic variants, (3) better define the genomic architecture of common CVDs, interindividual response to common cardiovascular drugs, and the phenomena of incomplete penetrance and variable expressivity in monogenic CVDs, (4) determine the clinical utility of established GRSs and pharmacogenomic tests through prospective RCTs, and (5) 
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